Goldman Sachs
DRUG

Goldman Sachs’s Bright Minds Biosciences DRUG Stock Holding History

Goldman Sachs’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.38M Buy
133,689
+59,320
+80% +$4.66M ﹤0.01% 3298
2026
Q1 		$5.43M Buy
74,369
+25,822
+53% +$2.08M ﹤0.01% 3617
2025
Q4 		$3.79M Buy
+48,547
New +$3.24M ﹤0.01% 4004
2025
Q2 		– Sell
-22,222
Closed -$802K – 6152
2025
Q1 		$802K Buy
+22,222
New +$813K ﹤0.01% 4850

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Goldman Sachs's DRUG Position: Q2 2026 in Review

Goldman Sachs increased its Bright Minds Biosciences (DRUG) stake by 80% in Q2 2026, buying an estimated $4.66M and bringing the position to 133,689 shares worth $9.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3298.

Goldman Sachs first reported a position in DRUG in Q1 2025 and has held it in 4 quarters since. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Goldman Sachs held 133,689 shares of Bright Minds Biosciences worth $9.38M as of Q2 2026.
  • Goldman Sachs bought 59,320 Bright Minds Biosciences shares in Q2 2026, an estimated $4.66M.
  • Bright Minds Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3298 holding.
  • Goldman Sachs first reported a position in Bright Minds Biosciences in Q1 2025 and has held it in 4 quarters since.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.